Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline

Ed Silverman for STAT News writes about the newly-appointed CEO to the AMR Action Fund.

The author writes about the history of the AMR Action Fund and its goal to "acquire or invest in small companies that can develop two to four novel antibiotics by 2030 and replenish the global supply chain with needed treatments."

The author references the Access to Medicine Foundation's Antimicrobial Resistance Benchmark when detailing the current landscape for the development of new antibiotics within the pharmaceutical industry.

Read the full article here.